结直肠癌基因融合的合理检测:以MSI且RAS-BRAF野生型转移性结直肠癌作为系统筛查的目标人群
本研究在常规实践中评估MSI/RAS-BRAF野生型(WT)结直肠癌患者中基因融合的发生率,采用商业化的NGS融合panel检测。130例MSI结直肠癌中43例(33%)为KRAS-NRAS-BRAF野生型;其中27例质控后RNA适合分析的MSI/RAS-BRAF WT样本中7例(25.9%)检出基因融合,主要涉及NTRK1/3(n=5)、ALK(n=1)和BRAF(n=1)。作者结论支持两步法分子筛查:转移性结直肠癌患者常规检测MSI和RAS/BRAF,仅MSI/RAS-BRAF WT者再用专用NGS RNA panel筛查基因融合。
要点
- 130例MSI结直肠癌中43例(33%)为KRAS-NRAS-BRAF野生型。
- 27例质控合格的MSI/RAS-BRAF WT样本中7例(25.9%)检出基因融合。
- 融合主要涉及NTRK1/3(n=5)、ALK(n=1)和BRAF(n=1)。
核心结论
- 本研究证实MSI/RAS-BRAF WT结直肠癌患者是靶向基因融合过度代表的亚群。
- 结果支持两步法分子筛查:转移性结直肠癌常规检测MSI和RAS/BRAF,仅MSI/RAS-BRAF WT者再用专用NGS RNA panel筛查融合。
研究设计与样本
- 本研究在常规实践中评估MSI/RAS-BRAF WT结直肠癌患者中基因融合的发生率,采用商业化的NGS融合panel检测。
- 共纳入130例MSI结直肠癌肿瘤,其中43例(33%)为KRAS-NRAS-BRAF野生型。
- 27例MSI/RAS-BRAF WT样本经质控后RNA适合分析。
主要发现
- 130例MSI结直肠癌中43例(33%)为KRAS-NRAS-BRAF野生型。
- 27例质控合格的MSI/RAS-BRAF WT样本中7例(25.9%)检出基因融合。
- 检出的融合主要涉及NTRK1/3(n=5),以及ALK(n=1)和BRAF(n=1)。
关键数值与推荐
- 基因融合在结直肠癌患者中不超过1%。
- MSI/RAS-BRAF WT样本中基因融合检出率为25.9%(7/27)。
临床怎么用
- 作者支持采用两步法分子筛查:转移性结直肠癌患者常规检测MSI和RAS/BRAF,仅MSI/RAS-BRAF WT者再用专用NGS RNA panel筛查基因融合。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gene fusions provide access to new therapeutic opportunities for patients treated for a colorectal cancer (CRC). However, they do not excess 1% of patients. A better identification of patients in whom gene fusions are highly prevalent is a major issue in a therapeutic and medico-economics perspective. This study assesses the rates of gene fusions in CRC patients with MSI/RAS-BRAFWT in our routine practice detected with a commercially available NGS-based fusion panel. Among the 130 MSI CRC tumors, 43 (33%) were KRAS-NRAS-BRAFWT. A gene fusion was detected in 7 (25.9%) of the 27 MSI/RAS-BRAFWT samples, which had RNA suitable for analysis after quality control. These fusions involved mainly NTRK1/3 (n = 5), as well as ALK (n = 1) and BRAF (n = 1). In the present study, we confirm that patients with MSI/RAS-BRAFWT CRCs represent a subpopulation in which targetable gene fusions are overrepresented. Our results support the use of a two-step algorithm for molecular screening, in which metastatic CRC patients would have routine MSI and RAS/BRAF testing, and then only those with MSI/RAS-BRAFWT would be screened with dedicated NGS RNA panel for gene fusions.
引用
- Delaye M, Ibadioune S, Julié C, et al. Rational testing for gene fusion in colorectal cancer: MSI and RAS-BRAF wild-type metastatic colorectal cancer as target population for systematic screening. Eur J Cancer. 2022. PMID: 35598360. doi:10.1016/j.ejca.2022.04.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。